4-(2-Aminoethyl)benzenesulfonyl fluoride attenuates tumor-necrosis-factor-α-induced blood-brain barrier opening

Pál Megyeri, László Németh, Karen M. Pabst, Michael J. Pabst, Mária A. Deli, Csongor S. Ábrahám

Research output: Contribution to journalArticle

19 Citations (Scopus)


The effect of serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) was investigated on the prevention of tumor-necrosis-factor-α (TNF-α)-induced blood-brain barrier opening. TNF-α (10,000 IU) was injected intracarotidly to newborn pigs pretreated with 0, 2.4, 4.8, 9.6 and 19.2 mg/kg AEBSF (n=6 in each group). AEBSF dose-dependently inhibited the TNF-α-induced increase in the blood-brain barrier permeability for sodium fluorescein (MW=376) in all of the five brain regions examined, while only 19.2 mg/kg AEBSF could significantly (P<0.05) decrease the change in Evan's blue-albumin (MW=67,000) transport in two regions. In conclusion, AEBSF attenuates vasogenic brain edema formation. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)207-211
Number of pages5
JournalEuropean Journal of Pharmacology
Issue number2
Publication statusPublished - Jun 18 1999


  • AEBSF [4-(2-aminoethyl)benzenesulfonyl] fluoride
  • Blood-brain barrier
  • Brain edema
  • Serine protease inhibitor
  • TNF-α (tumor necrosis factor-α)

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of '4-(2-Aminoethyl)benzenesulfonyl fluoride attenuates tumor-necrosis-factor-α-induced blood-brain barrier opening'. Together they form a unique fingerprint.

  • Cite this